Abstract
Long-term Maintenance of ≥50% Migraine Response with Eptinezumab Treatment in Patients with 2–4 Prior Preventive Migraine Treatment Failures (S22.008)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have